Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11114285 | 0.85 | KDM4E (0.65) | KDM4EGAARAB9ANPC1CYP1A2 | |
| SCHEMBL29591698 | 0.84 | KDM4E (0.62) | KDM4EGAARAB9ANPC1CYP1A2 | |
| SCHEMBL647157 | 0.84 | KDM4E (0.62) | KDM4EGAARAB9ANPC1CYP1A2 | |
| SCHEMBL9347143 | 0.84 | KDM4E (0.62) | KDM4EGAARAB9ANPC1CYP1A2 | |
| SCHEMBL6392056 | 0.81 | KDM4E (0.65) | KDM4EGAARAB9ANPC1CYP1A2 | |
| SCHEMBL6892140 | 0.81 | KDM4E (0.65) | KDM4EGAARAB9ANPC1CYP1A2 | |
| SCHEMBL12359712 | 0.81 | KDM4E (0.59) | KDM4EGAARAB9ANPC1CYP1A2 | |
| SCHEMBL13381366 | 0.81 | KDM4E (0.65) | KDM4EGAARAB9ANPC1CYP1A2 | |
| SCHEMBL11109764 | 0.81 | MAPT (0.60) | KDM4EGAARAB9ANPC1CYP1A2 | |
| SCHEMBL31337824 | 0.81 | KDM4E (0.65) | KDM4EGAARAB9ANPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1011670-A4 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | LILLY CO ELI (US) | 2004-10-27 | — | — | EP | claimed |
| JP-2003525901-A | — | — | 2003-09-02 | — | — | JP | claimed |
| US-20030119860-A1 | METHOD FOR TRATMENT OF NON-RHEUMATOID ARTHRITIS | ELI LILLY AND COMPANY | 2003-06-26 | — | — | US | claimed |
| US-20030087944-A1 | Method for the treatment of renal dysfunction with spla2 inhibitors | CONCORD (HK) INTERNATIONAL EDUCATION LIMITED (HK) | 2003-05-08 | — | — | US | claimed |
| EP-1265607-A2 | METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA 2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | claimed |
| EP-0779273-B1 | Naphthyl glyoxamides as sPLA2 inhibitors | LILLY CO ELI (US) | 2002-03-20 | — | — | EP | claimed |
| WO-2001066110-A2 | METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-09-13 | — | — | WO | claimed |
| WO-2001066111-A1 | COMPOSITIONS CONTAINING POTENTIAL SPLA2 INHIBITORS FOR THE TREATMENT OF PAIN | ELI LILLY AND COMPANY (US) | 2001-09-13 | — | — | WO | claimed |
| WO-2001055108-A2 | USE OF SPL A2 INHIBITORS FOR THE TREATMENT OF INFLAMMATION | ELI LILLY AND COMPANY (US) | 2001-08-02 | — | — | WO | claimed |
| US-6090850-A | SEPSIS SHOCK | ELI LILLY AND COMPANY (US) | 2000-07-18 | — | — | US | claimed |
| EP-1011670-A1 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | ELI LILLY AND COMPANY (US) | 2000-06-28 | — | — | EP | claimed |
| EP-1007056-A1 | METHOD FOR THE TREATMENT OF CYSTIC FIBROSIS | ELI LILLY AND COMPANY (US) | 2000-06-14 | — | — | EP | claimed |
| WO-1999016453-A1 | METHOD FOR THE TREATMENT OF CYSTIC FIBROSIS | ELI LILLY AND COMPANY (US) | 1999-04-08 | — | — | WO | claimed |
| WO-1999009978-A1 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | claimed |
| WO-1997021716-A1 | NAPHTHYL GLYOXAMIDES AS sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1997-06-19 | — | — | WO | claimed |
| EP-0779273-A1 | Naphthyl glyoxamides as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1997-06-18 | — | — | EP | claimed |
| US-7919617-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7897599-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-03-01 | — | — | US | disclosed |
| EP-0779273-A1 | Naphthyl glyoxamides as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1997-06-18 | — | — | EP | disclosed |
| EP-0779273-A1 | Naphthyl glyoxamides as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1997-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087944-A1 | Method for the treatment of renal dysfunction with spla2 inhibitors | IDO2, SPINT2, IDO1 | KDM4E 3856/4885GAA 1571/4885RAB9A 4212/4885 |
| US-20030119860-A1 | METHOD FOR TRATMENT OF NON-RHEUMATOID ARTHRITIS | TPP2, PLAAT2, PLAA | KDM4E 2708/4885GAA 685/4885RAB9A 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.